A phase II study of ZD1839 [gefitinib] and radiation in patients with squamous cell carcinoma of the skin.

Trial Profile

A phase II study of ZD1839 [gefitinib] and radiation in patients with squamous cell carcinoma of the skin.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Skin cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jan 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Planned end date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top